Mereo BioPharma Group plc filings document a U.K. clinical-stage biopharmaceutical issuer whose Nasdaq-listed ADSs represent ordinary shares. Recent Form 8-K reports furnish quarterly and annual financial results, rare-disease pipeline updates, conference presentation materials, cash runway disclosures, and clinical-program announcements for setrusumab, alvelestat, and related partnered assets.
The filing record also covers proxy governance, executive compensation and equity-award disclosures, board composition matters, ADS and ordinary-share listing information, and Nasdaq continued-listing compliance notices. These documents frame Mereo's capital structure, governance practices, material events, and development-stage public-company reporting.
Mereo BioPharma Group plc reported that officer Alexandra Hughes-Wilson received new share option grants on February 1, 2026. The awards cover 183,750 American Depositary Shares (ADS) at an exercise price of $0.44, 61,250 ADS at $1.00, and 195,000 ADS at $0.44.
For the 183,750-ADS option, 25% vests on February 1, 2027, with the rest vesting in equal monthly installments over the next three years. The 195,000-ADS option vests in substantially equal monthly installments over one year from the February 1, 2026 grant date. Each ADS represents five ordinary shares of Mereo BioPharma.
Mereo BioPharma Group plc reported that its General Counsel, Sermon Charles, received new share option awards on February 1, 2026. These are derivative securities giving the right to buy American Depositary Shares (ADS) at preset exercise prices.
The grants include options over 315,750 ADS at $0.44, 105,250 ADS at $1.00, and 295,000 ADS at $0.44, all expiring on February 1, 2036. One grant vests 25% on February 1, 2027 with the remainder vesting monthly over three years, while another vests in substantially equal monthly installments over one year from the grant date. Each ADS represents five ordinary shares.
Mereo BioPharma Group plc reported that Chief Executive Officer and director Denise Scots-Knight received new stock option awards on February 1, 2026. She was granted options to buy 1,035,000 American Depositary Shares at $0.44, 345,000 at $1.00, and 480,000 at $0.44, all held directly.
For the 1,035,000-share grant, 25% will vest and become exercisable on February 1, 2027, with the balance vesting in equal monthly installments over the following three years. The 480,000-share grant vests in substantially equal monthly installments over one year from the February 1, 2026 grant date. Each American Depositary Share represents five ordinary shares of the company.
Mereo BioPharma Group plc reported that its Chief Financial Officer, Christine Fox, received grants of share options on February 1, 2026. These derivative awards give her the right to buy 315,750 American Depositary Shares at an exercise price of $0.44, 105,250 ADS at $1.00, and 280,000 ADS at $0.44.
For the 315,750-option grant, 25% of the underlying shares vest and become exercisable on February 1, 2027, with the rest vesting in equal monthly installments over the following three years. The 280,000-option grant vests in substantially equal monthly installments over one year from the February 1, 2026 grant date. Each ADS represents five ordinary shares of Mereo BioPharma.
Mereo BioPharma Group plc updated its liquidity outlook and provided new investor materials. The company reported cash and cash equivalents of $41 million as of December 31, 2025, which it now expects will fund operations to mid-2027, extending its projected cash runway. Mereo also issued a corporate update press release and posted an investor presentation for use at the J.P. Morgan Healthcare Conference and other meetings, which are furnished as exhibits and not deemed filed under U.S. securities laws.
Mereo BioPharma Group plc received a Schedule 13G filing showing that funds associated with EcoR1 Capital and its principal Oleg Nodelman beneficially own 74,500,000 Ordinary Shares, equal to 9.4% of the outstanding Ordinary Shares. These holdings are held through 14,900,000 American Depositary Shares, each ADS representing 5 Ordinary Shares.
Within this total, EcoR1 Capital Fund Qualified, L.P. is reported as beneficially owning 69,802,840 Ordinary Shares, or 8.8% of the class, through 13,960,568 ADSs. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company. The reporting persons also formally disclaim group status and beneficial ownership beyond their pecuniary interest.
Mereo BioPharma Group plc received a Schedule 13G filing from investment firm 683 Capital and related parties reporting a significant passive stake. As of January 6, 2026, 683 Capital Partners, LP beneficially owned 65,083,815 ordinary shares, represented by 13,016,763 American Depositary Shares (ADS), which equals about 8.18% of the ordinary shares.
The percentage is based on 795,658,504 ordinary shares outstanding as of November 7, 2025. 683 Capital Management, LLC, as investment manager, and Ari Zweiman, as managing member, may each be deemed to share beneficial ownership. The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Mereo BioPharma.
Mereo BioPharma Group plc (MREO) furnished an update under Item 2.02, announcing financial results for the third quarter ended September 30, 2025, and recent corporate highlights. The full details are contained in a press release dated November 10, 2025, furnished as Exhibit 99.1.
The company noted that the information in Item 2.02 (including Exhibit 99.1) is being furnished, not filed, under the Exchange Act. MREO’s American Depositary Shares, each representing five ordinary shares, trade on The Nasdaq Stock Market LLC under the symbol MREO.
Mereo BioPharma Group plc reported a Q3 2025 net loss of $7.0 million, reduced from $15.0 million a year earlier, equal to a basic and diluted loss per share of $0.01 versus $0.02.
Revenue was minimal, with $500,000 recognized in the first nine months of 2025 from a leflutrozole milestone payment under the ReproNovo licensing agreement. Research and development expenses in Q3 rose to $4.3 million from $3.2 million, driven mainly by higher spending on setrusumab and alvelestat. General and administrative expenses were broadly stable at about $6.0 million in the quarter.
As of September 30, 2025, Mereo held cash and cash equivalents of $48.7 million, with total assets of $53.6 million and shareholders’ equity of $46.6 million. Management states that existing cash is expected to fund operations into 2027. During 2025, a Novartis convertible loan note was fully converted into ordinary shares, removing this debt and associated interest expense.
Frazier Life Sciences entities report passive holdings in Mereo BioPharma (MREO), detailing share counts, ADS equivalents and ownership percentages. The filing shows Frazier Life Sciences Public Fund, L.P. directly holds 32,430,690 Ordinary Shares, represented by 6,486,138 American Depositary Shares, equal to 4.1% of the issuer's 795,001,444 outstanding Ordinary Shares used for the percentage calculation. Additional Frazier entities hold 8,941,155 Ordinary Shares (1.1%, 1,788,231 ADS), 4,065,485 Ordinary Shares (0.5%, 813,097 ADS) and 1,763,230 Ordinary Shares (0.2%, 352,646 ADS). Voting and dispositive power over these holdings is reported as shared, with no sole voting or dispositive power asserted by the listed reporting persons. The statement corrects prior attributions by clarifying that committee members of certain general partners are not attributed beneficial ownership of the shares held by the funds. The filing also includes a certification that the securities were not acquired to influence control of the issuer and disclaims that the reporting persons are necessarily members of a group or beneficial owners beyond what is expressly stated.